Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

Journal of Neurochemistry

Volumn 105, Issue 6, 2008, Pages 2466-2476

  Molina Holgado, Francisco ^a   Gaeta, Alessandra ^a   Francis, Paul T ^a   Williams, Robert J ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid beta; Chelation therapy; Deferiprone; Iron; Oxidative stress

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 6 CARBOXYFLUORESCEIN; DEFERIPRONE; FERRIC ION; HYDROGEN PEROXIDE; PROPIDIUM IODIDE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CELL; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; HUMAN; HUMAN CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; CEREBRAL CORTEX; HUMANS; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PYRIDONES;

EID: 44649108912     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05332.x     Document Type: Article

References (42)

1. Adlard P. A. Bush A. I. (2006) Metals and Alzheimer's disease. J. Alzheimers Dis. 10, 145 163.
2. Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P. Halliwell B. (1997) A generalised increase in protein carbonyls in the brain of Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326 1329.
3. Andersen J. K. (2004) Iron dysregulation and Parkinson's disease. J. Alzheimers Dis. 6 (Suppl. 6 S47 S52.
4. Behl C., Davis J. B., Lesley R. Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817 827.
5. Ben-Shachar D., Kahana N., Kampel V., Warshawsky A. Youdim M. B. H. (2004) Neuroprotection by a novel brain permeable iron chelator VK-28, against 6-hydroxydopamine lesions in rats. Neuropharmacology 46, 254 263.
6. Berg D. Youdim M. B. (2006) Role of iron in neurodegenerative disorders. Top. Magn. Reson. Imaging 17, 5 17.
7. Brunk U. T. Terman A. (2002) Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Rad. Biol. Med. 33, 611 619.
8. Brunk U. T., Jones C. B. Sohal R. S. (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mutat. Res. 275, 395 403.
9. Bush A. I. (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23, 1031 1038.
10. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D. Mitchell J. B. (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47, 936 942.
11. 2+ and PI3-kinase. J. Neurochem. 80, 24 35.
12. Cuajungco M. P., Faget K. Y., Huang X., Tanzi R. E. Bush A. I. (2000) Metal chelation as a potential therapy for Alzheimer's disease. Ann. NY Acad. Sci. 920, 292 304.
13. Desagher S., Glowinski J. Premont J. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 16, 2553 2562.
14. Dexter D. T., Wells F. R. Lees A. J. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 381 389.
15. Floyd R. A. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236 245.
16. Floyd R. A. Hensley K. (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 23, 795 807.
17. Gaeta A. Hider R. C. (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146, 1041 1159.
18. Habgood M. D., Liu Z. D., Dehkordi L. S., Khodr H. H., Abbott J. Hider R. C. (1999) Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem. Pharmacol. 57, 1305 1310.
19. Halliwell B. (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634 1658.
20. Hashimoto M., Rockenstein E., Crews L. Masliah E. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 4, 21 36.
21. Hirsh E. C., Brandel J. P. Galle P. (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446 451.
22. Kuperstein F. Yavin E. (2003) Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity. J. Neurochem. 86, 114 125.
23. Liddell J. R., Hoepken H. H., Crack P. J., Robinson S. R. Dringen R. (2006) Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity. J. Neurosci. Res. 84, 578 586.
24. Lovell M. A. Markesbery W. R. (2006) Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr. Alzheimer Res. 3, 359 364.
25. Maguire-Zeiss K. A., Short D. W. Federoff H. J. (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res. Mol. Brain 134, 18 23.
26. Mandel S., Amit T., Bar-Am O. Youdim M. B. (2007) Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol. 82, 348 360.
27. Mattson M. P. (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann. NY Acad. Sci. 1012, 37 50.
28. Molina-Holgado F., Hider R. C., Gaeta A., Williams R. Francis P. (2007) Metals ions and neurodegeneration. Biometals 20, 639 654.
29. Ong W. Y. Halliwell B. (2004) Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage? Ann. NY Acad. Sci. 1012, 51 64.
30. Orth M. Tabrizi S. J. (2003) Models of Parkinson's disease. Mov. Disord. 18, 729 737.
31. Richardson D. R. (2004) Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. NY Acad. Sci. 1012, 326 341.
32. Rogers J. T. Lahiri D. K. (2004) Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Target 5, 535 551.
33. Rogers J. T., Randall J. D., Cahill C. M. et al. (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45518 45528.
34. Samanta S., Perkinton M. S., Morgan M. Williams R. J. (1998) Hydrogen peroxide enhances signal-responsive arachidonic acid release from neurons: role of MAP kinase. J. Neurochem. 70, 2082 2090.
35. Schubert D. Chevion M. (1995) The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 216, 702 707.
36. Selkoe D. J. (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924, 17 25.
37. Shaw L. M., Korecka M., Clark C. M., Lee V. M. Trojanowski J. Q. (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6, 295 303.
38. Sherki Y. G., Melamed E. Offen D. (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40, 959 975.
39. Swaiman K. F. Machen V. L. (1989) Effect of ferric nitrilotriacetate on predominantly cortical neuronal cell cultures. Neurochem. Res. 14, 683 688.
40. Wagner K. R., Sharp F. R., Ardizzone T. D., Lu A. Clark J. F. (2003) Heme and iron metabolism: role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23, 629 652.
41. Whitnall M. Richardson D. R. (2006) Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 13, 186 197.
42. Zecca L., Youdim M. B., Riederer P., Connor J. R. Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863 873.